Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,120,225 papers from all fields of science
Search
Sign In
Create Free Account
bazedoxifene
Known as:
1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-
, bazedoxifene/conjugated estrogens
An indole derivative and third-generation selective estrogen receptor modulator (SERM) with potential antineoplastic activity. Upon administration…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Broader (3)
Bone Density Conservation Agents
Indoles
Selective Estrogen Receptor Modulators
Narrower (3)
Duavee
TSE 424
WAY-140424
NCIt Antineoplastic Agent Terminology
bazedoxifene / Estrogens, Conjugated (USP)
bazedoxifene acetate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.
Marie-Cécile Valéra
,
P. Gourdy
,
F. Trémollieres
,
J. Arnal
Maturitas
2015
Corpus ID: 206801620
Review
2014
Review
2014
Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
S. Silverman
,
B. Komm
,
S. Mirkin
Maturitas
2014
Corpus ID: 25237326
Review
2014
Review
2014
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan
H. Ohta
,
J. Solanki
Osteoporosis International
2014
Corpus ID: 629833
The incidence of osteoporosis-related fractures in Asian countries is steadily increasing. Optimizing osteoporosis treatment is…
Expand
2014
2014
A double‐blind, randomized, ascending, multiple‐dose study of bazedoxifene in healthy postmenopausal women
W. McKeand
,
G. Orczyk
,
J. Ermer
,
A. Chines
Clinical pharmacology in drug development
2014
Corpus ID: 10163257
Bazedoxifene is a novel selective estrogen receptor modulator in clinical development for the prevention and treatment of…
Expand
Review
2013
Review
2013
Management of osteoporosis in primary care before and after the result of densitometry: treatments in real practice versus the recommended by guidelines. CANAL study.
A. Naranjo
,
J. Rosas
,
S. Ojeda
,
E. Salas
Reumatología Clínica
2013
Corpus ID: 3890040
2013
2013
Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women
H. Yu
,
J. Racketa
,
A. Chines
,
S. Mirkin
Climacteric
2013
Corpus ID: 25453228
ABSTRACT Objective The aim of this study was to examine the number of hot flush symptom-free days in symptomatic postmenopausal…
Expand
Review
2010
Review
2010
New treatment modalities in osteoporosis.
E. Canalis
Endocrine Practice
2010
Corpus ID: 13527226
OBJECTIVE To describe recently discovered agents for the management of osteoporosis. METHODS A literature review (PubMed search…
Expand
Review
2009
Review
2009
New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab
S. Silverman
Current Osteoporosis Reports
2009
Corpus ID: 37693958
Intravenous (IV) zoledronic acid, a new once-yearly bisphosphonate therapy, is approved by the US Food and Drug Administration…
Expand
2009
2009
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
B. Clarke
2009
Corpus ID: 74869772
2008
2008
Efficacy and safety of bazedoxifene in postmenopausal Asian women
L. Xu
,
K. Tsai
,
+4 authors
G. Constantine
Osteoporosis International
2008
Corpus ID: 24513006
SummaryThis 6-month study examined the efficacy and safety of bazedoxifene 20 mg in postmenopausal Asian women. Bazedoxifene…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE